EUVIMEDEUVIMED entdecken
Crossref

A Novel Dual-targeting PD-1 and TL1A Bispecific Antibody with Synergistic Effect for Immune Disorders Treatment 2255198

Hongyan Shang, Duqing Jiang, Xiao Huang, Jianming Sun, Yurong Qin, Guojin Wu, Chengze Ni, Jing Guan, Jordan Zhu, Xiaoqiang Kang, Hong Ling

The Journal of Immunology · 01.08.2026 · 215 (Supplement_1)

DOI: 10.1093/jimmun/vkag141.254 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Immunology, online erschienen am 28.07.2026. Verfasst von Hongyan Shang und 10 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Programmed cell death protein 1 (PD-1), an inhibitory immune checkpoint on T cells, maintains immune homeostasis. Dysregulated PD-1 signaling is implicated in autoimmune pathogenesis, whereas insufficient activity may result in uncontrolled T-cell responses. TNF-like ligand 1A (TL1A), a member of the TNF superfamily, engages DR3 to activate NF-κB pathway, thereby amplifying pro-inflammatory cytokine production and contributing to chronic inflammation and fibrosis. We developed a novel bispecific antibody that co-targets PD-1 and TL1A to achieve synergistic inhibition of pathogenic immune activation, with relevance to both PD-1 and TL1A driven immune disorders.

Methods

Bispecific antibodies were generated by fusing novel PD-1 agonistic and TL1A antagonistic VHH domains in a tetra-valent format. A series of candidates were evaluated through comprehensive in vitro assays including assessment of binding kinetics, PD-1/PD-L1/2 blocking, PD-1 agonism, TL1A-DR3 blocking, ADCC, and T-cell suppression. In vivo efficacy was assessed in a mouse colitis model.

Results

The leading bispecific antibody binds to a unique PD-1 epitope, enhances PD-1—PD-L1/2 engagement, and inhibits TL1A—DR3 binding. It demonstrated dose-dependent PD-1 pathway agonism and TL1A antagonism, suppressing T-cell activation, proliferation and cytokine production. Robust ADCC activity against PD-1+ T cells was observed. In vivo, it showed superior efficacy over comparator monotherapies in ameliorating colitis.

Conclusion

The anti-PD-1xTL1A bispecific antibody exerts synergistic immunomodulation through three complementary mechanisms: enhancement of PD-1 inhibitory signaling, blockade of the TL1A—DR3 pathway, and selective depletion of PD-1-expressing T cells via ADCC. It significantly mitigates T-cell-driven inflammation in vitro and ameliorates disease activity in vivo, supporting its potential as a novel treatment for autoimmune diseases such as IBD (inflammatory bowel disease). Funding Source Nanjing Leads Biolabs Co., Ltd Topic Categories Therapeutic Approaches to Autoimmunity (THER)

Zitieren

APA

Shang, H., Jiang, D., Huang, X., Sun, J., Qin, Y., Wu, G., Ni, C., Guan, J., Zhu, J., Kang, X., & Ling, H. (2026). A Novel Dual-targeting PD-1 and TL1A Bispecific Antibody with Synergistic Effect for Immune Disorders Treatment 2255198. The Journal of Immunology, 215(Supplement_1). https://doi.org/10.1093/jimmun/vkag141.254

Vancouver

Shang H, Jiang D, Huang X, Sun J, Qin Y, Wu G, et al. A Novel Dual-targeting PD-1 and TL1A Bispecific Antibody with Synergistic Effect for Immune Disorders Treatment 2255198. The Journal of Immunology. 2026;215(Supplement_1). doi:10.1093/jimmun/vkag141.254

BibTeX
@article{Shang2026,
  author = {Shang, Hongyan and Jiang, Duqing and Huang, Xiao and Sun, Jianming and Qin, Yurong and Wu, Guojin and Ni, Chengze and Guan, Jing and Zhu, Jordan and Kang, Xiaoqiang and Ling, Hong},
  title = {A Novel Dual-targeting PD-1 and TL1A Bispecific Antibody with Synergistic Effect for Immune Disorders Treatment 2255198},
  journal = {The Journal of Immunology},
  year = {2026},
  volume = {215},
  number = {Supplement_1},
  doi = {10.1093/jimmun/vkag141.254}
}
Kostenlos starten →